Scouting Pharmaceuticals for Commercialization in Russia/CIS and Global Named Patient Programs (NPPs)

Our client seeks to identify technologies and products for in-licensing with regional exclusivity in Russia, CIS, and Global Markets.
The company is a fast growing, Swiss-headquartered pharmaceutical group of companies focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to facilitate patient access to medicines across the unlicensed and licensed product phases.
Russia/CIS Region Focus Areas:
Full commercial representation of the technology/product in Russia and CIS region (including Ukraine and Baltics)
Various market access routes available including Named Patient Sales and an application for Market Authorization (MA), to be determined on a product basis
Priorities:
- Innovative Products with therapeutic value
- Inpatient Products preferred, but also open to Outpatient
- Focus on Pharmaceuticals, but innovative Medical Devices could also be of interest
Indications / Areas / Products of Interest include:
- Oncology
- Dermatology
- Orphan Disease (Diabetes)
- Cardiovascular (Myocardial Infarction)
- Hospital Products (Antibiotics / Septic Shock)
- Neurology (Multiple Sclerosis / Parkinson’s Disease)
Excluded Technology Areas include:
- Generics
- Alzheimer’s Disease
Desired Level of Development:
- Approved / Marketed products – U.S. FDA and/or EU approved products are preferred
- Pre-registration products
- Phase 3 acceptable
Global Markets Focus Areas:
Therapeutics available through Managed Access Program (MAP)
Therapeutics available through Named Patient Access Program (NPP) transitioning to MA for Switzerland
Priority: Innovative Products with an unmet patient need
Indications / Areas / Products of Interest include:
- Oncology
- Orphan Diseases
- Any other disease areas with unmet patient needs
Excluded Technology Areas Include:
- Generics
- Biosimilars
- OTCs
Desired level of development:
- Approved / Marketed products – at least in one major market (irrespectively which one)
- Pre-registration products (Companies with commercial approach in place)
No Comments